Related Experiment Video

Updated: Mar 7, 2026

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.7K

Pharmacologic Targeting of S6K1 in PTEN-Deficient Neoplasia

Hongqi Liu1, Xizhi Feng2, Kelli N Ennis3

  • 1Department of Cancer Biology, Vontz Center for Molecular Studies, University of Cincinnati, Cincinnati, OH 45267-0521, USA; Institute of Medical Biology, Chinese Academy of Medical Science and Peking Union Medical College, Kunming, Yunnan 650118, China.

Cell Reports
|March 2, 2017
PubMed

Insights

S6K1 inhibitors show promise for PTEN-deficient cancers. AD80 effectively targets S6K1 and AXL, offering a new therapeutic strategy for leukemia and glioblastoma by preventing cancer cell recovery.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • PTEN deficiency is common in various cancers.
  • S6K1 signaling is crucial for cell growth and survival.
  • Targeting S6K1 is a potential therapeutic strategy for PTEN-deficient malignancies.

Purpose of the Study:

  • To evaluate the therapeutic potential of S6K1 inhibitors in PTEN-deficient T cell leukemia and glioblastoma.
  • To investigate the mechanisms underlying differential responses to S6K1 inhibitors.

Main Methods:

  • In vitro and in vivo studies using PTEN-deficient cell lines and mouse models.
  • Treatment with S6K1 inhibitors (LY-2779964 and AD80).
  • Kinome analysis and assessment of signaling pathways (mTOR-S6K1).

Main Results:

  • AD80 demonstrated selective cytotoxicity in PTEN-deficient cells and rescued leukemia-bearing mice.
  • LY-2779964 was less effective due to rapid S6K1 signaling recovery.
  • AD80 inhibited both S6K1 and AXL (a TAM family tyrosine kinase).
  • Combined targeting of S6K1 and TAMs enhanced cytotoxicity in glioblastoma cells.

Conclusions:

  • AD80 is a promising therapeutic agent for PTEN-deficient cancers.
  • Combination therapy targeting S6K1 and TAMs represents a viable strategy for PTEN-deficient malignancies.
Keywords:
AD80AXLBMS-777607LY-2779964PF4708671PtenS6K1TAMglioblastomaleukemia

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.0K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K